Ab 2.7 restored response to ESA treatment in hHepc knockin AI mice. (A) Experimental scheme detailing administration time of BA (3 × 10⁸ particles/mouse, intraperitoneally), antihepcidin (or control) antibody (1 mg subcutaneously), and ESA (100 μg/kg darbepoetin alfa, subcutaneously) or saline control. Hb was measured before and after treatment (n = 3-5/group). (B) Hep1 AI mice showed declining Hb when treated with 4× control antibody. Treatment with either ESA or Ab2.7 had no effect but combination treatment was effective at preventing the Hb decline. (C) Hep1 mice showed a dose-response to Ab2.7. Statistics represent comparison of Hb values at day 13: **P < .01.